Related Experiment Video
Updated: Jan 10, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Therapeutic Potential of Acalypha wilkesiana in Type 2 Diabetes: A Review
Samuel Inshutiyimana1, Patel Dineshbhai Yesh2, Michael Matiop Aleu2
1Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya.
Background:
Type 2 diabetes mellitus (T2DM) refers to a chronic metabolic disorder that results from insulin resistance, leading to impaired insulin action and uncontrolled plasma glucose levels. Acalypha wilkesiana is among medicinal plants that are ethnobotanically used in the management of T2DM. However, there is a paucity of information on its antidiabetic potential. This review is aimed at providing a current understanding of the mechanism of action, potency, and safety of Acalypha wilkesiana in T2DM therapy.
Methods:
A narrative review was thoroughly conducted by searching Google Scholar and PubMed databases using a predefined combination of keywords. All gathered articles were reviewed for the content regarding T2DM, Acalypha wilkesiana, mechanism of action, and safety. A total of 44 articles were considered in this review.
Results:
Several experimental studies revealed that extracts of Acalypha wilkesiana inhibit α-glucosidase and α-amylase, which normally break down carbohydrates postprandially. Notably, the ethanolic root bark extracts of Acalypha wilkesiana have shown lower inhibitory concentrations compared to those of both the plant extracts in other solvents and the acarbose drug, emphasizing its greater potency. Additionally, the leaves of Acalypha wilkesiana have been reported to have no harmful effects on the red blood cells of diabetic rabbits and can even restore the alloxan-induced impairment of pancreas and spleen cells.
Conclusion:
Acalypha wilkesiana demonstrates antihyperglycemic activity and can reverse the dysfunction of critical organs. It promises advances in the development of antihyperglycemic agents which are more efficacious and safer than synthetic agents. However, clinical trials should be conducted to establish human-tailored doses, ensuring an improved safety profile of the plant in the treatment of T2DM.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Acute Pancreatitis II: Clinical Manifestations and Management
